Understanding the drivers behind disease with the 100,000 Genomes Project
Do CLL patients with mutated immunoglobulin receptors respond better to therapy?
Key considerations for mutation detection in CLL
From the bench to bedside: AML treatment
Safety data for the PI3Kδ inhibitor umbralisib for lymphoid malignancies